Zealand Pharma — Maj 2024
-
Nogle kommentarer til det?
-
tak
-
"These results are in line with the outcomes observed with shorter term treatment using lower doses of other incretin-based therapies," said David Kendall, MD, Chief Medical Officer of Zealand Pharma".
-
tak
-
"Our ongoing 13-week Phase 1b dose-titration trial is currently evaluating higher doses of dapiglutide up to 13 mg, and based on the tolerability profile observed to date, we will seek to investigate even higher doses going forward. We expect topline results from our Phase 1b trial in the second half of this year."
-
Vedr. bivirkninger: "Overall, the number of events observed were lower than have been reported from studies of other incretin-based therapies, and none led to treatment discontinuation in this trial".
-
Konklusion: Vægttab som andre lign. lavdosis incretinbaserede terapier, men med en bedre bivirkningsprofil.
-
tak, Helge
-
Jeg tror de fleste investorer har fokus på de kommende data for amylin. Der skal dog nok være nogen som ikke kender forskel på de midler der er i pipelinen - og hvor de er henne i deres udvikling.
-
Jeg ser selv frem til efterfølgende data på lowgrade inflammation på DREAM studiet. De er ikke nævnt i dagens meddelelse.
-
Enig SMADK.
-
Prøv se på data fra slide 21 og sammenlig med dages data... https://www.zealandpharma.com/investor/corporate-presentation-pdf/
-
Se højeste dosis og kurvens retning 4 ugers data vs dagens
12 uger. -
0,0% yderligere vægttab
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind